FTC Says Martin Shkreli Streamed Himself Ignoring Lifetime Pharma Ban

The Federal Trade Commission announced Wednesday that former biotech executive Martin Shkreli broadcast a live video in which he appeared to breach the lifetime prohibition that bars him from participating in the pharmaceutical sector. The agency said the clip, posted to a public streaming service, showed Shkreli handling drug‑related paperwork and discussing potential business deals, actions that directly contravene the terms of his settlement.

Shkreli first entered the national spotlight in 2015 when his company, Turing Pharmaceuticals, raised the price of Daraprim, a medication used to treat a parasitic infection, by more than 4,000 percent. The dramatic increase sparked widespread outrage and led to a criminal investigation that uncovered a separate securities‑fraud scheme. In 2018, a federal jury convicted him of securities fraud, and he was sentenced to seven years in prison.

Alongside the criminal sentence, a civil settlement with the FTC imposed a permanent ban on Shkreli’s involvement in any capacity within the pharmaceutical industry. The decree bars him from manufacturing, marketing, or even consulting on drug products, and it requires him to refrain from any activities that could influence the market for prescription medicines.

According to the FTC’s statement, the livestream—recorded in early August—showed Shkreli seated at a desk surrounded by medical‑industry literature. He spoke openly about “getting back into the game” and referenced contacts at a venture‑capital firm that invests in biotech startups. The video was uploaded to a popular live‑streaming platform and remained accessible for several hours before it was removed following a takedown request.

In response, the commission said it is evaluating a range of enforcement actions, including additional monetary penalties and a possible request for a court to impose stricter supervisory conditions. The FTC emphasized that violations of lifetime bans are rare but taken seriously, as they undermine the agency’s ability to protect consumers from fraud and abusive practices.

The incident reignites debate over how effectively regulatory bodies can monitor high‑profile individuals who operate primarily online. Consumer advocates argue that the Shkreli case highlights a need for more robust digital surveillance tools, while civil‑liberties groups caution against overreach. Regardless of the outcome, the FTC’s next steps will likely set a precedent for handling similar breaches in an increasingly connected marketplace.